Pelthos Therapeutics Inc.

For the period ended Dec 31, 2025. Filed Mar 19, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 19, 2026

PTHS$8.90-5.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Power of Attorney (included on the signature pages herein)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Pelthos Therapeutics Inc.
Date: March 19, 2026	By:	/s/ Scott Plesha
		Name: Scott Plesha
		Title: Chief Executive Officer and President (Principal Executive Officer)
Date: March 19, 2026	By:	/s/ Francis Knuettel II
		Name: Francis Knuettel II
		Title: Chief Financial Officer, Treasurer and Secretary (Principal Financial Officer, Principal Accounting Officer)

SIGNATURES AND POWER OF ATTORNEY

We, the undersigned directors and officers of Pelthos Therapeutics Inc., hereby severally constitute and appoint Scott Plesha and Frank Knuettel II, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

	Pelthos Therapeutics Inc.
Date: March 19, 2026	By:	/s/ Scott Plesha
		Name: Scott Plesha
		Title: Chief Executive Officer, President and Director
Date: March 19, 2026	By:	/s/ Peter Greenleaf
		Name: Peter Greenleaf
		Chairman of the Board of Directors
Date: March 19, 2026	By:	/s/ Matthew Pauls
		Name: Matthew Pauls
		Director
Date: March 19, 2026	By:	/s/ Andrew Einhorn
		Name: Andrew Einhorn
		Director
Date: March 19, 2026	By:	/s/ Todd Davis
		Name: Todd Davis
		Director
Date: March 19, 2026	By:	/s/ Richard Baxter
		Name: Richard Baxter
		Director
Date: March 19, 2026	By:	/s/ Ezra Friedberg
		Name: Ezra Friedberg
		Director
Date: March 19, 2026	By:	/s/ Richard Malamut
		Name: Richard Malamut
		Director

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 199)	F-2
Report of Independent Registered Public Accounting Firm (PCAOB ID 688)	F-3
Consolidated Balance Sheets	F-4
Consolidated Statements of Operations and Comprehensive Loss	F-5
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)	F-6
Consolidated Statements of Cash Flows	F-8
Notes to Consolidated Financial Statements	F-10

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.